Allergy Therapeutics (AGY)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

5.67p
   
  • Change Today:
    -0.81p
  • 52 Week High: 7.70
  • 52 Week Low: 2.65
  • Currency: UK Pounds
  • Shares Issued: 4,766.44m
  • Volume: 60,203
  • Market Cap: £270.10m
  • RiskGrade: 268

AGY Overview

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments. We believe that transformational outcomes for patients are achieved by directly treating the cause, rather than just managing symptoms. Our vaccines are aluminium free. Driving convenience; our ultra-short course treatments make life easier and increase adherence.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -63.9% -35.6%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 5.6 4.7
Pr/Book 83.3  
Latest F'cast
Revenue -7.4% 17.4%
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

AGY Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-20 78.20 8.07 1.11p 12.6 0.1 +102% n/a 0.0%
30-Jun-21 84.33 3.66 0.45p 55.6 n/a -60% n/a 0.0%
30-Jun-22 72.77 (12.66) (2.14)p n/a n/a n/a n/a 0.0%
30-Jun-23 59.59 (41.77) (6.43)p n/a n/a n/a n/a 0.0%
30-Jun-24 55.20 (39.17) (1.07)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AGY Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-25 64.80 (23.10) (0.66)p n/a n/a n/a n/a 0.0%
30-Jun-26 80.90 (9.70) (0.40)p n/a n/a n/a n/a 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

AGY Company Announcements

Interim Results for six months ended 31 Dec 2024 31-Mar-2025 07:00 RNS
Advancement to final phase of PROTECT trial 27-Mar-2025 07:00 RNS
New Executive Long Term Incentive Awards 03-Mar-2025 07:00 RNS

AGY ShareCast News

Allergy Therapeutics starts dosing peanut allerg... 27-Mar-2023 ShareCast
Allergy Therapeutics confident in funding as res... 20-Jan-2023 ShareCast
Allergy Therapeutics pauses production at Freema... 04-Oct-2022 ShareCast

AGY Top Newspaper Links

Allergy drug firm hit by trials setback 12-Jul-2007 The Independent
Need to Know: Global Business Briefing 25-Mar-2006 Times

Latest AGY Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AGY Market Data

Currency UK Pounds
Share Price 5.67p
Change Today -0.81p
% Change -12.55 %
52 Week High 7.70
52 Week Low 2.65
Volume 60,203
Shares Issued 4,766.44m
Market Cap £270.10m
RiskGrade 268

AGY Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
67.4% below the market average67.4% below the market average67.4% below the market average67.4% below the market average67.4% below the market average
65.96% below the sector average65.96% below the sector average65.96% below the sector average65.96% below the sector average65.96% below the sector average
Price Trend
83.15% above the market average83.15% above the market average83.15% above the market average83.15% above the market average83.15% above the market average
87.76% above the sector average87.76% above the sector average87.76% above the sector average87.76% above the sector average87.76% above the sector average
Income Not Available
Growth
53.98% below the market average53.98% below the market average53.98% below the market average53.98% below the market average53.98% below the market average
54.84% below the sector average54.84% below the sector average54.84% below the sector average54.84% below the sector average54.84% below the sector average

AGY Dividends

No dividends found

Trades for 31-Mar-2025

Time Volume / Share Price
13:16 14,947 @ 5.63p
13:16 108 @ 6.50p
11:00 5,000 @ 6.50p
11:00 100 @ 6.50p
11:00 4,900 @ 6.50p

AGY Key Personnel

CEO Manuel Llobet

Top of Page